User login
The role of moisturizers and lubricants in genitourinary syndrome of menopause and beyond
Michael L. Krychman, MD
Executive Director, Southern California Center for Sexual Health and Survivorship Medicine
Newport Beach, California
Alyssa Dweck, MD
CareMount Medical, PC, Mt. Kisco, New York
Assistant Clinical Professor, Department of Obstetrics, Gynecology, and Reproductive Science
Mount Sinai School of Medicine, New York, New York
Consultant, Massachusetts General Hospital, Vincents Memorial Ob/Gyn Service
Boston, Massachusetts
Sheryl Kingsberg, PhD
Chief, Division of Behavioral Medicine, Department of Obstetrics & Gynecology
University Hospitals, Cleveland Medical Center
Professor, Reproductive Biology and Psychiatry
Case Western Reserve University School of Medicine
Cleveland, Ohio
Lisa Larkin, MD
President, Lisa Larkin, MD, & Associates
Cincinnati, Ohio
Dr. Krychman reports receiving research support from New England Research Institutes (NERI) and being a consultant for Palatin, Shionogi, Inc, Sylk USA, TherapeuticsMD, and Valeant Pharmaceuticals; a speaker for Shionogi and Valeant; and an advisor for Uniderm.
Dr. Dweck reports being a consultant to Uniderm and a speaker for Bayer Pharmaceuticals.
Dr. Kingsberg reports receiving grant or research support from Palatin; being a consultant to Acerus, AMAG, Emotional Brain, EndoCeutics, Materna, NovoNordisk, Nuelle, Palatin, Pfizer, Scientific Strategic Solutions, Shionogi, TherapeticsMD, and Valeant Pharmaceuticals; and being a speaker for Valeant.
Dr. Larkin reports being a consultant and speaker for Valeant Pharmaceuticals.
OBG Management and the roundtable faculty do not endorse any specific product mentioned over another in this roundtable discussion.
Michael L. Krychman, MD
Executive Director, Southern California Center for Sexual Health and Survivorship Medicine
Newport Beach, California
Alyssa Dweck, MD
CareMount Medical, PC, Mt. Kisco, New York
Assistant Clinical Professor, Department of Obstetrics, Gynecology, and Reproductive Science
Mount Sinai School of Medicine, New York, New York
Consultant, Massachusetts General Hospital, Vincents Memorial Ob/Gyn Service
Boston, Massachusetts
Sheryl Kingsberg, PhD
Chief, Division of Behavioral Medicine, Department of Obstetrics & Gynecology
University Hospitals, Cleveland Medical Center
Professor, Reproductive Biology and Psychiatry
Case Western Reserve University School of Medicine
Cleveland, Ohio
Lisa Larkin, MD
President, Lisa Larkin, MD, & Associates
Cincinnati, Ohio
Dr. Krychman reports receiving research support from New England Research Institutes (NERI) and being a consultant for Palatin, Shionogi, Inc, Sylk USA, TherapeuticsMD, and Valeant Pharmaceuticals; a speaker for Shionogi and Valeant; and an advisor for Uniderm.
Dr. Dweck reports being a consultant to Uniderm and a speaker for Bayer Pharmaceuticals.
Dr. Kingsberg reports receiving grant or research support from Palatin; being a consultant to Acerus, AMAG, Emotional Brain, EndoCeutics, Materna, NovoNordisk, Nuelle, Palatin, Pfizer, Scientific Strategic Solutions, Shionogi, TherapeticsMD, and Valeant Pharmaceuticals; and being a speaker for Valeant.
Dr. Larkin reports being a consultant and speaker for Valeant Pharmaceuticals.
OBG Management and the roundtable faculty do not endorse any specific product mentioned over another in this roundtable discussion.
Michael L. Krychman, MD
Executive Director, Southern California Center for Sexual Health and Survivorship Medicine
Newport Beach, California
Alyssa Dweck, MD
CareMount Medical, PC, Mt. Kisco, New York
Assistant Clinical Professor, Department of Obstetrics, Gynecology, and Reproductive Science
Mount Sinai School of Medicine, New York, New York
Consultant, Massachusetts General Hospital, Vincents Memorial Ob/Gyn Service
Boston, Massachusetts
Sheryl Kingsberg, PhD
Chief, Division of Behavioral Medicine, Department of Obstetrics & Gynecology
University Hospitals, Cleveland Medical Center
Professor, Reproductive Biology and Psychiatry
Case Western Reserve University School of Medicine
Cleveland, Ohio
Lisa Larkin, MD
President, Lisa Larkin, MD, & Associates
Cincinnati, Ohio
Dr. Krychman reports receiving research support from New England Research Institutes (NERI) and being a consultant for Palatin, Shionogi, Inc, Sylk USA, TherapeuticsMD, and Valeant Pharmaceuticals; a speaker for Shionogi and Valeant; and an advisor for Uniderm.
Dr. Dweck reports being a consultant to Uniderm and a speaker for Bayer Pharmaceuticals.
Dr. Kingsberg reports receiving grant or research support from Palatin; being a consultant to Acerus, AMAG, Emotional Brain, EndoCeutics, Materna, NovoNordisk, Nuelle, Palatin, Pfizer, Scientific Strategic Solutions, Shionogi, TherapeticsMD, and Valeant Pharmaceuticals; and being a speaker for Valeant.
Dr. Larkin reports being a consultant and speaker for Valeant Pharmaceuticals.
OBG Management and the roundtable faculty do not endorse any specific product mentioned over another in this roundtable discussion.
Dr. Michael Krychman details new and in-the-pipeline treatment options for vulvovaginal atrophy
In an audiocast summarizing his Sunday Lunch Talk at the Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) on May 3, 2015, Dr. Michael L. Krychman discusses new treatment options for vulvar and vaginal atrophy (VVA), including over-the-counter and prescription products and procedures. He emphasizes that a better understanding of the physical and anatomic changes in menopause has led to these improved options.
Dr. Krychman also recommends the use of "genitourinary syndrome of menopause" (GSM), new terminology for VVA suggested by the International Society for the Study of Women's Sexual Health and the North American Menopause Society.1
Among the products Dr. Krychman details are neogyn® Feminine Soothing Cream (neogyn, inc., Switzerland); RepHresh™ Vaginal Gel (Church & Dwight Co., Inc., Princeton, New Jersey); Replens™ Long-Lasting Vaginal Moisturizer (Church & Dwight); silicone- and water-based lubricants (Replens™ Silky Smooth Lubricant [Church & Dwight]; JuvaGyn® Feminine Moisturizer [neogyn, inc.]); and ospemifene (Osphena®, Shionogi Inc., Florham Park, New Jersey).
Dr. Krychman is interested in a new laser procedure for VVA/GSM, but comments that more study is needed before he can recommend its general use. He also talks about other exciting alternatives in the pipeline.
- Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;11(12):2865–2872.
In an audiocast summarizing his Sunday Lunch Talk at the Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) on May 3, 2015, Dr. Michael L. Krychman discusses new treatment options for vulvar and vaginal atrophy (VVA), including over-the-counter and prescription products and procedures. He emphasizes that a better understanding of the physical and anatomic changes in menopause has led to these improved options.
Dr. Krychman also recommends the use of "genitourinary syndrome of menopause" (GSM), new terminology for VVA suggested by the International Society for the Study of Women's Sexual Health and the North American Menopause Society.1
Among the products Dr. Krychman details are neogyn® Feminine Soothing Cream (neogyn, inc., Switzerland); RepHresh™ Vaginal Gel (Church & Dwight Co., Inc., Princeton, New Jersey); Replens™ Long-Lasting Vaginal Moisturizer (Church & Dwight); silicone- and water-based lubricants (Replens™ Silky Smooth Lubricant [Church & Dwight]; JuvaGyn® Feminine Moisturizer [neogyn, inc.]); and ospemifene (Osphena®, Shionogi Inc., Florham Park, New Jersey).
Dr. Krychman is interested in a new laser procedure for VVA/GSM, but comments that more study is needed before he can recommend its general use. He also talks about other exciting alternatives in the pipeline.
In an audiocast summarizing his Sunday Lunch Talk at the Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) on May 3, 2015, Dr. Michael L. Krychman discusses new treatment options for vulvar and vaginal atrophy (VVA), including over-the-counter and prescription products and procedures. He emphasizes that a better understanding of the physical and anatomic changes in menopause has led to these improved options.
Dr. Krychman also recommends the use of "genitourinary syndrome of menopause" (GSM), new terminology for VVA suggested by the International Society for the Study of Women's Sexual Health and the North American Menopause Society.1
Among the products Dr. Krychman details are neogyn® Feminine Soothing Cream (neogyn, inc., Switzerland); RepHresh™ Vaginal Gel (Church & Dwight Co., Inc., Princeton, New Jersey); Replens™ Long-Lasting Vaginal Moisturizer (Church & Dwight); silicone- and water-based lubricants (Replens™ Silky Smooth Lubricant [Church & Dwight]; JuvaGyn® Feminine Moisturizer [neogyn, inc.]); and ospemifene (Osphena®, Shionogi Inc., Florham Park, New Jersey).
Dr. Krychman is interested in a new laser procedure for VVA/GSM, but comments that more study is needed before he can recommend its general use. He also talks about other exciting alternatives in the pipeline.
- Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;11(12):2865–2872.
- Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;11(12):2865–2872.
